NMPA approval of antifungal Cresemba for invasive aspergillosis in China.-Pfizer + Basilea
Pfizer submitted separate marketing authorization applications for the intravenous formulations of Cresemba for the treatment of invasive aspergillosis and mucormycosis and these are under regulatory review by the Center for Drug Evaluation at the NMPA.
The license agreement between Basilea and Pfizer covers Europe (excluding the Nordic countries), Russia, Turkey, Israel, as well as China (including Hong Kong and Macao) and sixteen countries in the Asia Pacific region. In addition to receiving mid-teen royalties on sales, Basilea remains eligible for further milestone payments of up to approximately $600 million under the agreement with Pfizer.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins